CN102834388B - Cgrp受体拮抗剂 - Google Patents
Cgrp受体拮抗剂 Download PDFInfo
- Publication number
- CN102834388B CN102834388B CN201180016888.2A CN201180016888A CN102834388B CN 102834388 B CN102834388 B CN 102834388B CN 201180016888 A CN201180016888 A CN 201180016888A CN 102834388 B CN102834388 B CN 102834388B
- Authority
- CN
- China
- Prior art keywords
- compound
- cgrp
- pharmaceutically acceptable
- methyl
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XJGVSYPLZCOMED-VUUHIHSGSA-N COC(C(C1)([C@@H]1O)NC(OCc1ccccc1)=O)=O Chemical compound COC(C(C1)([C@@H]1O)NC(OCc1ccccc1)=O)=O XJGVSYPLZCOMED-VUUHIHSGSA-N 0.000 description 1
- STFUIEDYPRMRNN-UHFFFAOYSA-N COC(C(NC(OCc1ccccc1)=O)=C)=O Chemical compound COC(C(NC(OCc1ccccc1)=O)=C)=O STFUIEDYPRMRNN-UHFFFAOYSA-N 0.000 description 1
- 0 Cc(cc1C)cc(C)c1N* Chemical compound Cc(cc1C)cc(C)c1N* 0.000 description 1
- XTSGDBVWWOJSNF-RKBNTCOGSA-N Cc1c2[nH]ncc2cc([C@H](C2)C2(C(N(CC2)CCN2C2CCN(C)CC2)=O)NC(N(CC2)CCC2C2=Cc(cccc3)c3NC2=O)=O)c1 Chemical compound Cc1c2[nH]ncc2cc([C@H](C2)C2(C(N(CC2)CCN2C2CCN(C)CC2)=O)NC(N(CC2)CCC2C2=Cc(cccc3)c3NC2=O)=O)c1 XTSGDBVWWOJSNF-RKBNTCOGSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31901510P | 2010-03-30 | 2010-03-30 | |
| US61/319,015 | 2010-03-30 | ||
| PCT/US2011/028168 WO2011123232A1 (en) | 2010-03-30 | 2011-03-11 | Cgrp receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102834388A CN102834388A (zh) | 2012-12-19 |
| CN102834388B true CN102834388B (zh) | 2014-07-16 |
Family
ID=43896902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180016888.2A Active CN102834388B (zh) | 2010-03-30 | 2011-03-11 | Cgrp受体拮抗剂 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8481546B2 (enExample) |
| EP (1) | EP2552906B1 (enExample) |
| JP (1) | JP5908455B2 (enExample) |
| KR (3) | KR101747477B1 (enExample) |
| CN (1) | CN102834388B (enExample) |
| AR (1) | AR080746A1 (enExample) |
| AU (1) | AU2011233627B2 (enExample) |
| BR (1) | BR112012024785B1 (enExample) |
| CA (1) | CA2794950C (enExample) |
| CL (1) | CL2012002739A1 (enExample) |
| CY (1) | CY1117593T1 (enExample) |
| DK (1) | DK2552906T3 (enExample) |
| EA (1) | EA022815B1 (enExample) |
| ES (1) | ES2562610T3 (enExample) |
| HR (1) | HRP20160287T1 (enExample) |
| HU (1) | HUE028735T2 (enExample) |
| IL (1) | IL221665A (enExample) |
| MX (1) | MX2012010725A (enExample) |
| NZ (1) | NZ603231A (enExample) |
| PE (1) | PE20130340A1 (enExample) |
| PL (1) | PL2552906T3 (enExample) |
| PT (1) | PT2552906E (enExample) |
| RS (1) | RS54608B1 (enExample) |
| SG (1) | SG183918A1 (enExample) |
| SI (1) | SI2552906T1 (enExample) |
| SM (1) | SMT201600078B (enExample) |
| TW (1) | TWI483937B (enExample) |
| WO (1) | WO2011123232A1 (enExample) |
| ZA (1) | ZA201207292B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222889A1 (zh) | 2023-04-28 | 2024-10-31 | 成都思倍博医药科技有限公司 | 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
| GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
| EP3863629A4 (en) * | 2018-10-13 | 2022-06-22 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of cgrp antagonists |
| SG11202106721VA (en) * | 2019-01-20 | 2021-07-29 | Biohaven Pharm Holding Co Ltd | Cgrp antagonists for treating migraine breakthrough |
| JP7654561B2 (ja) | 2019-04-11 | 2025-04-01 | アール．ピー． シェーラー テクノロジーズ エルエルシー | 浸透性が低いタンパク質、ペプチド、及び小分子の経口送達用の製剤 |
| US20220401439A1 (en) * | 2019-12-17 | 2022-12-22 | Biohaven Pharmaceutical Holding Company Ltd. | Intranasal pharmaceutical compositions of cgrp inhibitors |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び／又は発生の低減 |
| WO2022217008A1 (en) | 2021-04-09 | 2022-10-13 | Teva Czech Industries S.R.O | Solid state forms of zavegepant and process for preparation thereof |
| WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药（上海）有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
| IL320431A (en) | 2022-11-09 | 2025-06-01 | Teva Czech Ind S R O | Crystalline forms of zibagen hydrochloride and process for their preparation |
| CN116003387B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代吲唑丙酰胺类化合物、药物组合物和用途 |
| WO2025003905A1 (en) | 2023-06-29 | 2025-01-02 | Pfizer Inc. | Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide |
| CN119462607B (zh) * | 2023-08-10 | 2025-11-28 | 南京宁丹新药技术股份有限公司 | 一类喹啉酮衍生物及其用途 |
| CN117551081A (zh) * | 2023-11-13 | 2024-02-13 | 北京康立生医药技术开发有限公司 | 一种偏头痛治疗药物新的制备方法 |
| ES3027457A1 (es) | 2023-12-13 | 2025-06-13 | Moehs Iberica Sl | Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos |
| WO2025238595A1 (en) | 2024-05-16 | 2025-11-20 | Olon S.P.A. | Process for preparing (r)-2-amino-3-(7-methyl-1h-indazol-5-yl) methyl propanoate, and use thereof as intermediate for the synthesis of zavegepant |
| WO2026033478A1 (en) | 2024-08-09 | 2026-02-12 | Olon S.P.A. | Process for preparing 3-piperidin-4-il-1h- quinolin-2-one or a salt thereof and its use as an intermediate for the preparation of pharmaceutical active ingredients antagonists of the cgrp peptide receptor |
| CN119306698B (zh) * | 2024-10-09 | 2025-10-21 | 浙江工业大学 | 一种制备扎维吉泮中间体的新方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1671711A (zh) * | 2002-06-05 | 2005-09-21 | 布里斯托尔-迈尔斯斯奎布公司 | 降钙素基因相关肽受体拮抗剂 |
| CN101495480A (zh) * | 2006-05-03 | 2009-07-29 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| WO2005084672A1 (de) | 2004-03-03 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel |
| US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
| WO2010006168A2 (en) | 2008-07-09 | 2010-01-14 | University Of Rochester | Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor |
-
2011
- 2011-03-02 US US13/038,550 patent/US8481546B2/en active Active
- 2011-03-11 KR KR1020127028213A patent/KR101747477B1/ko active Active
- 2011-03-11 PL PL11710087T patent/PL2552906T3/pl unknown
- 2011-03-11 SI SI201130765A patent/SI2552906T1/sl unknown
- 2011-03-11 JP JP2013502610A patent/JP5908455B2/ja active Active
- 2011-03-11 AU AU2011233627A patent/AU2011233627B2/en active Active
- 2011-03-11 PE PE2012001746A patent/PE20130340A1/es active IP Right Grant
- 2011-03-11 BR BR112012024785-9A patent/BR112012024785B1/pt active IP Right Grant
- 2011-03-11 EP EP11710087.5A patent/EP2552906B1/en active Active
- 2011-03-11 HU HUE11710087A patent/HUE028735T2/en unknown
- 2011-03-11 ES ES11710087.5T patent/ES2562610T3/es active Active
- 2011-03-11 KR KR1020187011875A patent/KR20180049168A/ko not_active Ceased
- 2011-03-11 WO PCT/US2011/028168 patent/WO2011123232A1/en not_active Ceased
- 2011-03-11 SG SG2012065744A patent/SG183918A1/en unknown
- 2011-03-11 DK DK11710087.5T patent/DK2552906T3/en active
- 2011-03-11 RS RS20160164A patent/RS54608B1/sr unknown
- 2011-03-11 CN CN201180016888.2A patent/CN102834388B/zh active Active
- 2011-03-11 PT PT117100875T patent/PT2552906E/pt unknown
- 2011-03-11 CA CA2794950A patent/CA2794950C/en active Active
- 2011-03-11 EA EA201270751A patent/EA022815B1/ru not_active IP Right Cessation
- 2011-03-11 HR HRP20160287TT patent/HRP20160287T1/hr unknown
- 2011-03-11 MX MX2012010725A patent/MX2012010725A/es active IP Right Grant
- 2011-03-11 NZ NZ603231A patent/NZ603231A/en unknown
- 2011-03-11 KR KR1020177015456A patent/KR101854249B1/ko active Active
- 2011-03-30 TW TW100111106A patent/TWI483937B/zh active
- 2011-03-30 AR ARP110101057A patent/AR080746A1/es not_active Application Discontinuation
-
2012
- 2012-08-27 IL IL221665A patent/IL221665A/en active IP Right Grant
- 2012-09-28 ZA ZA2012/07292A patent/ZA201207292B/en unknown
- 2012-09-28 CL CL2012002739A patent/CL2012002739A1/es unknown
-
2016
- 2016-03-21 SM SM201600078T patent/SMT201600078B/xx unknown
- 2016-03-24 CY CY20161100254T patent/CY1117593T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1671711A (zh) * | 2002-06-05 | 2005-09-21 | 布里斯托尔-迈尔斯斯奎布公司 | 降钙素基因相关肽受体拮抗剂 |
| CN101495480A (zh) * | 2006-05-03 | 2009-07-29 | 百时美施贵宝公司 | 作为降钙素基因相关肽受体拮抗剂的受限化合物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024222889A1 (zh) | 2023-04-28 | 2024-10-31 | 成都思倍博医药科技有限公司 | 含氧代吡啶并脂肪环或脂杂环结构的化合物及其医药用途 |
| EP4703362A1 (en) | 2023-04-28 | 2026-03-04 | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd | Compound containing oxo-pyrido-aliphatic ring or aliphatic heterocyclic structure, and medical use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102834388B (zh) | Cgrp受体拮抗剂 | |
| JP7397452B2 (ja) | ヘテロアリールカルボキシアミド化合物 | |
| WO2008067566A1 (en) | Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators | |
| US9695176B2 (en) | Substituted imidazo[1,5-a]pyrazines as CGRP receptor antagonists | |
| WO2018222917A1 (en) | Ire1 small molecule inhibitors | |
| US10392367B2 (en) | IRE1 small molecule inhibitors | |
| CN113880772B (zh) | 一类cdk激酶抑制剂及其应用 | |
| JP4245682B2 (ja) | キノリン誘導体、イソキノリン誘導体、およびシンノリン誘導体、並びに抗炎症剤および抗アレルギー剤 | |
| US9745342B2 (en) | NMDA receptor modulators and prodrugs, salts, and uses thereof | |
| CN116514798A (zh) | 一种可抑制宫颈癌增殖的化合物及其制备方法与应用 | |
| HK1174914B (en) | Cgrp receptor antagonist | |
| US20040191312A1 (en) | 5-HT3 receptor agonists as neuroprotectors | |
| WO2025003905A1 (en) | Solid forms of (r)-n-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide | |
| TW202416975A (zh) | 萘并呋喃取代的戊二醯亞胺類化合物的晶型、製備方法及其應用 | |
| CN120081789A (zh) | 具有抗肿瘤活性的吡唑衍生物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |